1	Outbreak of severe community-acquired bacterial
2	infections from Streptococcus pyogenes, Streptococcus
3	pneumoniae, Neisseria meningitidis, and Haemophilus
4	<i>influenzae</i> among children in North Rhine-Westphalia
5	(Germany), October to December 2022
6	
7	Sarah C. Goretzki ¹ , MD, Mark van der Linden ² , PhD,
8	Andreas Itzek ² , PhD, Tom Hühne ¹ , MD, Roland O.
9	Adelmann ³ , MD, Firas Ala Eldin ⁴ , MD, Mohamed
10	Albarouni ⁵ , MD, Jan-Claudius Becker ⁶ , MD, Michael A.
11	Berghäuser ⁷ , MD, Thomas Boesing ⁸ , MD, Michael
12	Boeswald ⁹ , MD, Milian Brasche ¹⁰ , MD, Francisco Brevis ¹¹ ,
13	MD, Rokya Camara ¹² , MD, Clara Deibert ¹³ , MD, Frank
14	Dohle ¹⁴ , MD, Jörg Dolgner ¹⁵ , MD, Jan Dziobaka ¹⁶ , MD,
15	Frank Eifinger ¹⁷ , MD, Natalie Elting ¹⁸ , MD, Matthias
16	Endmann ¹⁹ , MD, Guido Engelmann ²⁰ , MD, Holger Frenzke ²¹ ,
17	MD, Monika Gappa ²² , MD, Bahman Gharavi ²³ , MD,
18	Christine Goletz ²⁴ , MD, Eva Hahn ²⁵ , MD, Yvonne
19	Heidenreich ²⁶ , MD, Konrad Heimann ¹⁰ , MD, Kai O.
20	Hensel ²⁷ , MD, Hans-Georg Hoffmann ²⁸ , MD, Marc
21	Hoppenz ²⁹ , MD, Gerd Horneff ³⁰ , MD, Helene Klassen ³¹ ,
22	MD, Cordula Körner-Rettberg ³² , MD, Alfred Längler ³³ , MD,
23	Pascal Lenz ³⁴ , MD, Klaus Lohmeier ³⁵ , MD, Andreas
24	Müller ³⁶ , MD, Frank Niemann ³⁷ , MD, Michael Paulussen ³⁸ ,
25	MD, Falk Pentek ³⁹ , MD, Ruy Perez ⁴⁰ , MD, Markus Pingel ⁴¹ ,
26	MD, Philip Repges ⁴² , MD, Tobias Rothoeft ⁴³ , MD, Jochen
27	Rübo ⁴⁴ , MD, Herbert Schade ⁴⁵ , MD, Robert Schmitz ⁴⁶ , MD,
28	Peter Schonhoff ⁴⁷ , MD, Jan N. Schwade ⁴⁸ , MD, Tobias
29	Schwarz ⁴⁹ , MD, Peter Seiffert ⁵⁰ , MD, Georg Selzer ⁵¹ , MD,
30	Uwe Spille ⁵² , MD, Carsten Thiel ⁵³ , MD, Ansgar Thimm ⁵⁴ ,
31	MD, Bartholomäus Urgatz ⁵⁵ , MD, Alijda van den Heuvel ⁵⁶ ,
32	MD, Tan van Hop ⁵⁷ , MD, Verena Giesen ⁵⁸ , MD, Stefan
33	Wirth ⁵⁹ , MD, Thomas Wollbrink ⁶⁰ , MD, Daniel Wüller ⁶¹ ,
34	MD, Ursula Felderhoff-Müser ¹ , MD, Christian Dohna-
35	Schwake ¹ , MD, Thiên-Trí Lâm ⁶² , PhD, Heike Claus ⁶² , PhD,
36	N. Bruns ¹ , MD
37	
38	Affiliations: ¹ Department of Pediatrics I (Neonatology, Pediatric Intensive Care, Pediatric
39	Neurology, and Pediatric Infectious Diseases), Department of Pediatrics, University
40	Hospital, Essen University of Duisburg-Essen, Essen, Germany; ² Department of Medical
41	Microbiology, German National Reference Centre for Streptococci, University Hospital
42	RWTH Aachen, Aachen, Germany; ³ Department of General Pediatrics, Klinikum
43	Oberberg, Kreiskrankenhaus Gummersbach, Gummersbach, Germany; ⁴ Department of
44	General Pediatrics, Helios Hospital Schwelm, Schwelm, Germany; ⁵ Division of
45	Rheumatology, Department of General Pediatrics, Asklepios Hospital Sankt Augustin,
46	Sankt Augustin, Germany; ^b Department of Pediatrics, Agaplesion Hospital Hagen, Hagen,
47	Germany; 'Division of Pediatric Intensive Care, Department of Pediatrics, Florence
48	Nightingale Hospital Kaiserswerth, Duesseldorf, Germany; ⁸ Division of Pediatric Intensive
49	Care, Department of Pediatrics, Protestant Hospital Bethel, University of Bielefeld,
50	Bielefeld, Germany; 'Department of Pediatrics, Sankt Franziskus Hospital Muenster,

Muenster, Germany; ¹⁰Division of Neonatology, Department of Pediatrics, University 51 Hospital, RWTH University of Aachen, Aachen, Germany; ¹¹Division of Pediatric 52 Intensive Care, Department of Pediatrics, Sana Hospitals Duisburg, Duisburg, Germany; 53 ¹²Division of Neonatology, Department of Pediatrics and Adolescent Medicine, GFO 54 Hospital Bonn, Bonn, Germany; ¹³Department of General Pediatrics, DRK Hospital 55 Kirchen, Kirchen, Germany; ¹⁴Division of Pediatric Intensive Care, Department of 56 Pediatrics, Sankt Louise Hospital Paderborn, Paderborn, Germany; ¹⁵Department of 57 General Pediatrics, GFO Hospital Dinslaken, Dinslaken, Germany; ¹⁶Department of 58 Microbiology, University of Essen, Essen, Germany; ¹⁷Division of Pediatric Intensive Care, 59 Department of Pediatrics, University Hospital, University of Cologne, Cologne, Germany; 60 ¹⁸Department of General Pediatrics, Evangelical Hospital Oberhausen, Oberhausen, 61 Germany; ¹⁹Department of General Pediatrics, St. Franziskus-Hospital Ahlen, Ahlen, 62 Germany; ²⁰Department of General Pediatrics, Lukas-Hospital Neuss, Neuss, Germany; 63 ²¹Department of General Pediatrics, Märkisch Hospital Luedenscheid, Luedenscheid, 64 Germany; ²²Department of General Pediatrics, Evangelical Hospital Duesseldorf, 65 Duesseldorf, Germany; ²³Department of General Pediatrics, Marien-Hospital Witten, 66 Witten, Germany; ²⁴Department of General Pediatrics, Staedtische Kliniken 67 Moenchengladbach, Elisabeth-Hospital Rheydt, Moenchengladbach, Germany; 68 69 ²⁵Department of Pediatrics and Adolescent Medicine, Sankt Agnes Hospital, Bocholt, Germany; ²⁶Department of General Pediatrics, Hospital Soest gGmbH, Soest, Germany; 70 ²⁷Division of Pediatric Intensive Care, Department of Pediatrics, Helios University Hospital 71 Wuppertal, Witten/Herdecke University, Wuppertal, Germany;²⁸Department of General 72 Pediatrics, Mathias-Stiftung, Rheine, Germany; ²⁹Division of Pediatric Intensive Care, 73 Department of Pediatrics, Children's Hospital Amsterdamer Str., Cologne, Germany; 74 ³⁰Department of Pediatrics, Asklepios Clinic Sankt Augustin GmbH, Sankt Augustin, 75 Germany; ³¹Department of Pediatrics and Adolescent Medicine, Hochsauerland Hospital, 76 77 Arnsberg, Germany; ³²Department of General Pediatrics, Marien-Hospital gGmbH, Wesel, Germany; ³³Department of Pediatrics, Gemeinschaftskrankenhaus Herdecke, University of 78 Witten/Herdecke, Herdecke, Germany; ³⁴Department of General Pediatrics, Hospital 79 Leverkusen GmbH, Leverkusen, Germany; ³⁵Division of Neonatology and Pediatric 80 Cardiology, Department of General Pediatrics, Heinrich Heine University, Duesseldorf, 81 Germany; ³⁶Department of Neonatology and Pediatric Intensive Care Medicine, University 82 of Bonn, Germany; ³⁷Department of General Pediatrics, Marien-Hospital Gelsenkirchen, 83 Gelsenkirchen, Germany; ³⁸Division of Oncology and Haematology, Departement of 84 85 General Pediatrics, Vestische Hospital of Children and Adolescents Medicine Datteln, University of Witten/Herdecke, Datteln, Germany; ³⁹Department of Pediatrics, Elisabeth-86 Hospital Essen, Essen, Germany; ⁴⁰Division of Pediatric Intensive Care, Department of 87 Pediatrics, Helios Hospital Krefeld, Krefeld, Germany; ⁴¹Department of General Pediatrics, 88 DRK Hospital Siegen gGmbH, Siegen, Germany; ⁴²Department of General Pediatrics, Porz, 89 Cologne, Germany; ⁴³Division of Neonatology and Pediatric Intensive Care, University 90 Children's Hospital, Ruhr University of Bochum, Bochum, Germany;⁴⁴Department of 91 General Pediatrics, St. Antonius Hospital Kleve, Kleve, Germany;⁴⁵Department of General 92 Pediatrics, Hospital Mechernich GmbH, Mechernich, Germany; ⁴⁶Department of Pediatrics, 93 Helios Clinic Duisburg, Duisburg, Germany; ⁴⁷Department of Pediatrics, Clemenshospital 94 Muenster, Muenster, Germany; ⁴⁸Department of General Pediatrics, Evangelical Hospital Lippstadt, Lippstadt, Germany; ⁴⁹Department of General Pediatrics, municipal Hospital Solingen, Solingen, Germany; ⁵⁰Department of Pediatrics, Helios Clinic Duisburg, 95 96 97 Duisburg, Germany; ⁵¹Division of Neonatology and Pediatric Intensive Care, Evangelical 98 Hospital Hamm, Hamm, Germany; ⁵²Department of General Pediatrics, Herford, Germany; 99 ⁵³Department of Pediatrics, St.-Clemens-Hospital Geldern, Geldern, Germany; 100 ⁵⁴Department of General Pediatrics, Sana-Hospital Remscheid, Remscheid, Germany; 101

102	⁵⁵ Department of General Pediatrics, AKH Hospital Viersen, Viersen, Germany; ⁵⁶ Division of Pediatric Intensive Care, Department of Pediatrics, University Hospital Muenster
103	Mugneter, Cormany: ⁵⁷ Department of Coneral Padiatrice, Hospital Oberhausen Starkrade
104	aGmbH Oberhausen Germany; ⁵⁸ Department of General Pediatrics, Bethanien Hospital
105	Moore Moore Cormony, ⁵⁹ Department of Dedictrice Holice Medical Contro Niederborg
107	Welbert, Cormony, ⁶⁰ Division of Padietria Intensive Core, Department of Padietries
107	Paramannshail Padiatria Haspital Calsankirahan Buar, Calsankirahan, Carmany:
100	⁶¹ Department of Dedictrics and Adolescent Medicine, Christonhorus Hearitel, Constald
109	Department of Pediatrics and Adolescent Medicine, Christophorus Hospital, Coesteld,
110	Germany, German National Reference Laboratory for Meningococci and Haemophilus
111	Cormony
112	Germany
113	
114	Address correspondence to New Draws, Department of Dedictrics I (New Stale or
115	Address correspondence to: Nora Bruns, Department of Pediatrics I (Neonatology, Dedictric Intensive Corres Dedictric Neurology, and Dedictric Infactions Discosses)
110	University Hearitel Essen University of Divisions Essen Helsterhouserstr 172, 40547
110	Easen Cormony Inore house Quit assen del 40,201,722,82208
110	Essen, Germany, [nora.oruns@uk-essen.de], +49-201-725-85508.
120	Short title: Savara hasterial infactions 2016 2023
120	Short the. Severe bacterial infections 2010 - 2023
121	Conflict of Interest Dicelogures (includes financial dicelogures); The other authors have
122	no conflicts of interest to disclose
123	no conflicts of interest to disclose.
124	Funding/Support: This research received no external funding. The surveillance of
125	invasive streptococcal infections in Germany at the German National Reference I aboratory
120	for Streptococci was funded by the Robert Koch Institute Berlin Germany (funding
122	number: 1369-235)
120	number: 1507-255)
130	Role of Funder/Sponsor (if any): The funder had no role in the design and conduct of the
131	study
132	Study.
133	Clinical Trial Registration (if any) : n/a
134	
135	Abbreviations: CI = confidence interval. CNS = central nervous system. CRC = capture-
136	recapture. eCRF = web-based case report forms. ENT = ears nose and throat. FSO =
137	Federal State Office. <i>H. influenzae = Haemophilus influenzae</i> . ICD-10-GM = international
138	classification of diseases 10 German modification. IOR = interguartile range. IRR =
139	incidence rate ratios. MC = multicentre study. N. meningitidis = Neisseria meningitidis.
140	NRL = National Reference Laboratories, NRLMHi = National Reference Laboratory for <i>N</i> .
141	<i>meningitidis</i> and <i>H. influenzae</i> , NRW = North Rhine-Westphalia, PCPC = pediatric
142	cerebral performance category, PICU = pediatric intensive care unit, rRNA = ribosomal
143	Ribonucleic acid, RSV = respiratory syncytial virus, S. pneumoniae =
144	Streptococcus pneumoniae, S. pyrogenes = Streptococcus pyogenes, SIRS = systemic
145	inflammatory response syndrome
146	
147	
148	
149	
150	
151	

152

- 153
- 154

155

156 Article Summary

In late 2022 and early 2023, hospitalizations for bacterial infections dramatically increased,
 causing deaths and contributing to a near-collapse of the pediatric health care system.

- 159
- 160
- 161 162

2 What's Known on This Subject

During the COVID-19 pandemic, incidences of bacterial infections strongly declined. In
 late 2022, several European countries observed strongly rebounding incidences of invasive
 infections from group A streptococci.

166 167

168 What This Study Adds

- 169 This study found up to 18-fold incidence rates of *S. pyogenes* in late 2022 and early 2023,
- accompanied by surges of *S. pneumoniae* and partially *H. influenzae*. Deaths were seven
- 171 times higher than expected.

172

173

174 Contributors Statement Page

175
176 Drs. Sarah C. Goretzki and Nora Bruns conceptualized and designed the study, carried out
177 analyses, drafted the initial manuscript, and critically reviewed and revised the manuscript.
178

179 Drs Tom Hühne, Roland O. Adelmann, Firas Ala Eldin, Mohamed Albarouni, Jan-Claudius

180 Becker, Michael A. Berghäuser, Thomas Boesing, Michael Boeswald, Milian Brasche,

181 Francisco Brevis, Rokya Camara, Clara Deibert, Frank Dohle, Jörg Dolgner, Jan Dziobaka,

- 182 Frank Eifinger, Natalie Elting, Matthias Endmann, Holger Frenzke, Monika Gappa,
- 183 Bahman Gharavi, Christine Goletz, Eva Hahn, Yvonne Heidenreich, Konrad Heimann,
- 184 Hans-Georg Hoffmann, Marc Hoppenz, Gerd Horneff, Helene Klassen, Cordula Körner-

185 Rettberg, Pascal Lenz, Klaus Lohmeier, Andreas Müller, Frank Niemann, Michael

186 Paulussen, Falk Pentek, Ruy Perez, Markus Pingel, Philip Repges, Tobias Rothoeft, Jochen

- 187 Rübo, Herbert Schade, Robert Schmitz, Peter Schonhoff, Jan N. Schwade, Tobias
- 188 Schwarz, Peter Seiffert, Georg Selzer, Uwe Spille, Carsten Thiel, Ansgar Thimm,
- 189 Bartholomäus Urgatz, Alijda van den Heuvel, Tan van Hop, Verena Giesen, Stefan Wirth,

190 Thomas Wollbrink, Daniel Wüller and Profs. Guido Engelmann, Kai O. Hensel, Alfred

- 191 Längler, collected data and critically reviewed and revised the manuscript.
- 192

Drs. Mark van der Linden, Andreas Itzek, Heike Claus and Thiên-Trí Lâm collected data,
carried analyses, and critically reviewed and revised the manuscript.

195

196 Profs. Ursula Felderhoff-Müser and Christian Dohna-Schwake conceptualized and

designed the study, coordinated and supervised data collection, and critically reviewed and
 revised the manuscript for important intellectual content.

199

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

- 202
- 203
- 204

205 Abstract [250 words max]

207 Background:

In late 2022, a surge of severe bacterial infections caused by S. pyogenes was reported in

209 several European countries, including Germany. This study assessed disease burden and

- severity of hospitalizations for community-acquired bacterial infections with S. pyogenes,
- 211 S. pneumoniae, N. meningitidis, and H. influenzae among children in North Rhine-
- 212 Westphalia (NRW), Germany, during the last quarter of 2022 compared to long-term
- 213 incidences.
- 214

206

215 Methods:

- Hospital cases due to bacterial infections between October and December 2022 were
- collected from 59/62 (95 %) children's hospitals in NRW and combined with surveillance
- data (2016 2023) from the national reference laboratories for streptococci, *N*.
- 219 meningitidis, and H. influenzae. Total cases in NRW and incidence rates from January 2016
- to March 2023 were estimated by capture-recapture analyses. Expected annual deaths from
- the studied pathogens were calculated from national death cause statistics.
- 222

223 **Results:**

- Between October and December 2022, 153 cases with high overall disease severity were
- reported with pneumonia being most common (59 %, n = 91). Incidence rates of bacterial
- infections declined at the beginning of the COVID-19 pandemic. In late 2022 and early
- 227 2023 a massive surge to levels unprecedented since 2016 was observed, mainly driven by *S*.
- 228 pyogenes and S. pneumoniae. Observed deaths during the study period exceeded the
- expected number for the entire year in NRW by far (7 vs. 0.9).
- 230

231 **Discussion:**

- The unprecedented peak of bacterial infections in late 2022 and early 2023 was caused by
- 233 various mechanisms intertwined that require close surveillance and improved precautionary
- 234 measures for future outbreaks.

235 Introduction

Since the outbreak of the COVID-19 pandemic in 2020, children's and adolescents' health has been challenged in numerous ways. Among others, a decline of bacterial infections and distorted periodicity of seasonal infection waves were observed across the world and affected all age groups.¹⁻⁵ An unforeseen result of reduced incidence of infections is the lack of natural immunity especially in the youngest.

Beginning in late fall 2022, rising numbers of severe bacterial infections caused by group A streptococci were reported from Spain, France, Great Britain, and other countries.⁶⁻⁹ At the same time in Germany, a massive wave of acute viral and bacterial infections caused a near-collapse of the pediatric health care system including out- and inpatient sectors and - most dramatically - overwhelmed pediatric intensive care capacities.¹⁰⁻¹² Pediatric health care providers in Germany claimed that this was an unprecedented public health emergency.

This study was designed to assess the burden of hospitalizations due to community-248 249 acquired bacterial infections by Streptococcus pyogenes (S. pyogenes), 250 Streptococcus pneumoniae (S. pneumoniae), Neisseria meningitidis (N. meningitidis), 251 and *Haemophilus influenzae* (*H. influenzae*) in the last guarter of 2022 compared to 252 seasonally expected infection waves since 2016; to identify driving pathogens, and 253 describe disease severity and outcomes. Accordingly, we combined five data sources for 254 comprehensive capture-recapture analyses: 1) A multicentre study (MC) conducted in 255 95 % of children's hospitals in the most populated state of Germany (North Rhine-256 Westphalia [NRW]) in the last quarter of 2022; 2) long-term surveillance data from 257 national reference laboratories for a) streptococci, b) N. meningitidis, and c) 258 Haemophilus influenzae; as well as 3) publicly accessible population and death cause statistics provided by the German Federal Statistical Office (FSO, Statistisches 259

260 Bundesamt, www.destatis.de).

261

- 262
- 263 Methods
- 264 <u>Study design:</u>

This is a retrospective multicentre cohort study to assess the burden of communityacquired severe bacterial infections in children and adolescents in NRW/Germany (NRW) between October 1^{st} and December 31^{st} of 2022. The results were combined with four data sources to deduce long-term trends.

269 First, clinical data were collected from 60 of 63 (95 %) children's hospitals in NRW. 270 Second, surveillance data from the national reference laboratories (NRL) for streptococci, N. meningitidis, and H. influenzae were matched with clinical cases from 271 272 the same period to conduct capture-recapture (CRC) analyses for each pathogen. Third, 273 monthly NRL-reported incidence numbers between January 2016 and March 2023 were 274 combined with population statistics published by the FSO to calculate incidence rates 275 and ratios. Fourth, death statistics by the FSO were accessed to calculate the expected number of deaths by bacterial infections per year and compare them with the numbers 276 277 observed in the MC study.

278

279 <u>Multicentre study</u>

280 <u>Study population:</u>

Children aged > 27 days and < 18 years admitted to a children's hospital in NRW during
the study period due to a community-acquired infection with *S. pyogenes*, *S. pneumoniae*, *N. meningitidis*, or *H. influenzae* were eligible. Children with catheterassociated infections from permanently indwelling catheters and cases of nosocomial
infections were excluded.

286

287 <u>Clinical data collection:</u>

Executives of all children's hospitals in NRW were invited to participate. Eligible patients were identified via positive test results for the bacterial pathogen of interest by the local microbiology departments or derived from diagnose related group codes (International Classification of Diseases, 10th revision, German modification). Eligibility was confirmed via retrospective chart review by the local investigators. Anonymized clinical data were collected via web-based case report forms (eCRF) hosted at www.limesurvey.org.

295

296 <u>Handling of duplicates:</u>

Duplicate reports in the dataset originating from inter-centre referrals were identified by discharge date information and destination of referral in the eCRF. The total duration of hospital stay in both hospitals was updated along with clinical information, and the duplicate case removed.

301

302 <u>Children's hospital capacities of North Rhine-Westphalia:</u>

Each participating hospital reported the number of non-surgical beds on pediatric wards (including neonatal and pediatric intensive care units) during the study period in the eCRFs. The capacities of the three non-participating centres were obtained by personal inquiry to the attending office of the respective children's hospital.

307

308 <u>National surveillance of invasive bacterial infections</u>

309 - Streptococci:

310 Reporting of invasive S. pneumoniae infections is mandatory in Germany. However,

311 surveillance of invasive streptococcal disease by the German national reference

312 laboratory for streptococci (NRLS) is based on voluntary reporting by primary 313 diagnostic laboratories, which are quested to send all streptococcal isolates from invasive infections (isolate sampled from a normally sterile anatomical site) to the 314 NRLS for detailed analyses. This includes mainly microbiological- (hemolysis- and 315 316 colony-size assessment, optochin sensitivity as well as bile solubility), biochemical-(leucine-aminopeptidase- and pyrrolidonylarylamidase-test), serological- (Neufeld-317 318 Quellung reaction) and molecularbiological methods (16S rRNA sequencing, emm-319 typing).

- 320
- 321 *N. meningitidis* and *H. influenzae*:

322 Mandatory reporting is required for cases of meningococcal meningitis and meningococcal septicaemia. Additionally, the detection of N. meningitidis in blood, 323 cerebrospinal fluid, petechiae, or other sterile sites, as well as the detection of 324 325 *H. influenzae* in blood or cerebrospinal fluid, must be reported. While it is voluntary to 326 submit bacterial isolates or clinical specimens to the National Reference Laboratory for N. meningitidis and H. influenzae (NRLMHi), up to 90% of the reported cases are 327 covered by the submissions to NRLMHi. Following species confirmation, 328 meningococcal serogroups and *H. influenzae* serotypes are determined through slide 329 330 agglutination using specific commercial antibodies.

331

332 <u>Population statistics of NRW:</u>

The end of year-populations of NRW and Germany from 2015 through 2022 were accessed at the FSO homepage (<u>www.destatis.de</u>). This information was used to calculate midyear populations as well as inhabitant percentage of children < 18 years of age.

337

338 <u>National death cause statistics:</u>

339 Nationwide death cause statistics were accessed at the FSO homepage and the yearly 340 numbers of deaths from streptococci, N. meningitidis, and H. influenzae infections were 341 extracted for 2016 to 2021 based on the diagnose code of the international classification 342 of diseases 10 German modification (ICD-10-GM) (Table 1). Because age grouping available at the FSO does not comply with the cut-off age for treatment in pediatric 343 344 departments, expected deaths were calculated only for children < 15 years of age. The number of nationwide expected deaths per year was extrapolated based on the 345 346 proportion of the pediatric population of NRW (22 %) compared to the total pediatric 347 population of Germany.

348

349 <u>Linkage of clinical and surveillance data:</u>

Clinical MC and NRL surveillance data of *S. pyogenes*, *S. pneumoniae*, *N. meningitidis and H. influenzae were matched by patient's age, sex, sample collection site and date,* identified pathogen and serotype if applicable. Direct record linkage by name or date of birth was inapplicable due to anonymization and prohibited by general data protection regulations.

355

356 <u>Statistical analyses:</u>

Continuous variables are presented as means with 95 % confidence intervals (CI) if evenly distributed and as median with interquartile range (IQR) if skewed. Discrete variables are presented as counts and relative frequencies. Descriptive statistics were stratified by pathogen. The dataset of the MC study contained no missing data.

Capture-recapture analyses (CRC) were conducted using a generalized log-linear model with Poisson distribution to estimate the number of non-captured cases with 95 % CIs and calculated the estimated number of total cases. Stratification to account for age-, 364 sex- or centre-specific probabilities could not be performed due to the overall low case365 numbers.

Monthly incidence rates per 100.000 child years (CY) were derived from total case numbers estimated by CRC analyses assuming a consistent reporting rate over time. Monthly incidence rate ratios (IRR) were calculated for the period from January 2020 to March 2023, with the corresponding months of 2016-2019 as references. Besides pathogen-specific incidence rates and IRRs, cumulative monthly incidence rates and IRRs for all four pathogens were calculated to assess the overall burden. 95 % CIs for rates and rate ratios were calculated based on the Poisson distribution.

SAS Enterprise Guide 8.3 (SAS Institute Inc., Cary, NC, USA) was used to perform
statistical analyses and produce figures.

375

376 <u>Ethics approval</u>

The study was approved by the Ethics Committee of the Medical Faculty of theUniversity of Duisburg-Essen (22-11045-BO).

379

380

381 **Results**

Fifty-nine of 62 (95 %) children's hospitals in NRW participated in the MC study, comprising 4066 of 4323 (94 %) self-reported pediatric hospital beds during the study period. At the end of 2022, 22 % of Germany's pediatric population lived in NRW. After subtracting the 6 % capacities from non-participating children's hospitals, the participating centers supplied medical care for approximately 20.7 % of the German pediatric population.

A total of 153 cases were reported with a median patient age of 4 years (IQR 1 - 7) and 56 % (n = 86) males (Table 2). Fifty-eight (38 %) of the reported cases were associated

390 with S. pyogenes, 62 (41 %) with S. pneumoniae, 2 (1 %) with N. meningitidis, 19 (12 391 %) with *H. influenzae*, and 12 (8 %) with other streptococcal species. The most frequent 392 presentation was pneumonia (n = 91, 59 %), followed by sepsis/systemic inflammatory 393 response syndrome/toxic shock syndrome (n = 28, 18%), skin or soft tissue infections (n 394 = 22, 14 %), and ear-nose-throat infections without cerebral invasion (n = 22, 14 %) (Table 2). Viral co-infections were observed in 71 (46%) cases, with variations 395 396 depending on the bacterial pathogen (Table 2). Intensive care unit admissions were 397 frequent (n = 90, 59%), as was mechanical ventilation (n = 67, 44 %), surgical source 398 control (n = 41, 27%), and use of vasopressors or inotropes (n = 26, 17%) (Table 2). 399 Substantial variation between pathogens was observed regarding clinical presentation 400 and performed supportive therapies (Figure 1). Eight children died (5 %), and five 401 patients (3 %) were discharged to a rehabilitation or care facility. Nonetheless, overall functional neurological outcome at hospital discharge in survivors was good (median 402 403 pediatric cerebral performance category (PCPC) = 1, IQR 1 - 2).

Capture-recapture analyses showed different degrees of overlap between the conducted MC study and the NRL surveillance data. For *N. meningitidis*, complete capture by the NRL was achieved, but the total case number (n = 6) was comparatively low, especially when compared to case estimates of *S. pneumoniae* (n_{estimated} = 232), *S. pyogenes* (n_{estimated} = 214), and *H. influenzae* (n_{estimated} = 95) (Table 3).

With onset of the COVID-19 pandemic, monthly *S. pyogenes* case numbers reported to the NRLS, monthly incidence rates and IRRs dropped, remained low until September 2022 and peaked in December 2022 (IRR 18.3 (95 % CI 6.3 – 88.8)) as well as March 2023 (IRR 14.7 (5.7 - 54.0)) (Figure 2a and S1a). *S. pneumoniae* also showed a decline during pandemic years but seasonal variations remained present throughout the threeyear period, with a remarkable peak in December 2022 (IRR 2.7 (1.7 - 4.7)) and February 2023 (IRR 3.2 (2.0 - 5.5)) (Figure 2b and S1b). For *N. meningitidis*, overall 416 case numbers were fairly low and no clear trend was observed throughout the 417 observation period except for an increase in March 2023 (IRR 1.7 (1.0 - 3.1)) (Figure 2c and S1c). H. influenzae, on the other hand, remained mainly within the seasonally 418 expected ranges except for November 2022 (IRR 7.8 (2.2 - 64.8)) and February 2023 419 420 (IRR 2.9 (1.1 - 10.8)) (Figure 2d and S1c). Overall, incidence rates and IRRs exhibited a decline at the onset of the pandemic, followed by a pathogen-specific degree of 421 422 recovery, reaching or surpassing pre-pandemic levels (Figure S1 and supplementary 423 table). Cumulative monthly incidence rates and IRRs declined at the beginning of the 424 pandemic, showed small peaks during the course of the pandemic, and peaked in 425 December 2022 and February 2023 (Figure 3 and supplementary table).

During the three-month MC study, the reported number of deaths in children < 15 years of age exceeded the expected number of deaths from bacterial infections for the entire year in NRW (7 observed; 1 expected). The causative pathogens were identified as *S. pyogenes* and *S. pneumoniae*, while no deaths were caused by *N. meningitidis* (2 expected) (Table 4).

431

432 **Discussion**

433 This multi-source study in Germany's most populous federal state detected a high 434 burden of pediatric general ward and pediatric intensive care unit admissions for 435 bacterial infections associated with S. pyogenes, S. pneumoniae, N. meningitidis, and H. influenzae in the last quarter of 2022. Disease severity was high with more than half of 436 437 the cases admitted to an intensive care unit and frequent requirement of invasive mechanical ventilation and vasoactive agents. Longitudinal assessment since 2016 438 revealed an unprecedented peak of bacterial infection-related hospitalizations in late 439 440 2022 and early 2023, primarily driven by S. pyogenes and S. pneumoniae. Deaths during the three-month period of the MC study were seven times higher than expected for the 441

442 entire year according to pre-pandemic death cause statistics.

A major finding that has already been reported in adults and children^{13, 14} was the marked overall decline of severe and invasive bacterial infections at the beginning of the COVID-19 pandemic. According to our study, this overall decline was shortly interrupted in fall 2021 but otherwise lasted until early summer 2022 when compulsory wearing of protective face masks was abrogated. However, decline patterns differed between the four bacterial pathogens examined in this study and were likely influenced by other factors than protective face masks.^{13, 15-20}

450 The decline of *S. pyogenes* infections from the onset of the pandemic until spring 2022 451 was also reported in France, followed by a sudden increase of non-invasive S. pyogenes infections.²¹ Similar to Germany, France and England also witnessed strong increases of 452 severe and invasive S. pyogenes infections during fall and winter of 2022.^{7, 22} These 453 surges were most likely induced by an overall rise in infection numbers with the 454 proportion of severe cases remaining constant, rather than changes in types, virulence or 455 toxicity.^{7, 23-25} A possible explanation is the discontinuation of face mask wearing among 456 children, which re-enabled droplet transmission of S. pyogenes, an essential mechanism 457 of infection.²⁶ Acute viral infections paving the way for bacterial superinfections are an 458 additional factor potentially contributing to the severity of the S. pyogenes infection 459 wave. This constellation is described for influenza virus in combination with S. 460 pyogenes and S. pneumoniae²⁷ and was also observed in our study. The theory of 461 superinfections as partial drivers of the surge is supported by the rise in consultations 462 and hospitalizations for severe acute respiratory disease in children and adolescents 463 464 during the peak of S. pyogenes infections in Germany in late 2022 reported by the Robert Koch-Institute.²⁸ 465

466 Viral infections likely also promoted the increase of *S. pneumoniae* infections.

467 Asymptomatic S. pneumoniae carriage and respiratory virus infection as starting point for invasive pneumococcal disease is well-described.²⁹ Our study found viral co-468 infections in 60 % of the S. pneumoniae cases, with influenza and respiratory syncytial 469 470 virus as the most common. During the pandemic years, the decline in pneumococcal infections in Germany was less consistent compared to the drop in S. pyogenes 471 472 infections, possibly explained by viral infection waves among children in spite of the pandemic measures.²⁸ In contrast to S. pyogenes infections, invasive pneumococcal 473 disease can be effectively prevented by vaccination.³⁰ Consequently, it is crucial to 474 475 establish and maintain high levels of vaccination rates to attenuate future outbreaks 476 triggered by viral waves. In Germany, pneumococcal vaccination coverage for children entering primary school increased from 15 % in 2010 to 83 % in 2017-2019 but is as low 477 as 2 % in the age group from 16 to 59 years, even in patients who suffer from high-risk 478 clinical conditions.^{31, 32} Of infants born in 2016, only 73 % received a full series of the 479 recommended pneumococcal vaccination scheme, vaccinations were frequently delayed, 480 and nearly a quarter of infants did not receive a booster dose.³³ This low vaccination 481 coverage calls for urgent improvement to enhance protection against opportunistic 482 pneumococcal infections during large-scale viral waves that are expected to persist in 483 the post-SARS-CoV-2 era. 484

Vaccines are also responsible for decreasing incidence rates of meningococcal infections with marked replacement by non-vaccinated serogroups W and Y in several countries.³⁴ In Germany, vaccination is recommended for serogroup C with an according decline of serogroup C infections since its introduction.³⁵ The trend of overall decreasing meningococcal disease was further enhanced during the COVID-19 pandemic ¹³ and also noticeable in our study with incidence rates below pre-pandemic average. Yet, in March 2023, an increase in meningococcal infection incidence above average was observed but characterized by very low absolute numbers. In contrast to *S. pneumoniae*, vaccine
coverage against meningococcal serogroup C in school starters in Germany is above 90
%.³² Unfortunately, no data are available on *N. meningitidis* serogroup B, but vaccine
coverage is likely to be very low because vaccination is not officially recommended and
thus not routinely covered by health insurances.

497 In the Netherlands, a decline of invasive infections during the COVID-19 pandemic was 498 observed for H. influenzae, unfortunately associated with an increase of vaccine-499 preventable serotype b.³⁶ In our study, *H. influenzae* hospitalizations during the 500 pandemic remained within seasonally expected ranges, showing only two peaks in 501 December of 2021 and 2022, respectively. However, despite vaccine coverage of 90 % in German children against *H. influenzae* b^{32} . IRRs have remained almost constantly 502 503 above one since June 2021, indicating a slight increase of non-vaccinated *H. influenzae* 504 infections that contribute to the overall burden of pediatric hospitalizations, especially 505 during seasonal waves of acute respiratory diseases.

Limitations of the study mainly derive from missing cases: Due to the incomplete coverage of children's hospitals in NRW, the MC study missed 6 % of pediatric hospital capacities. Cases treated outside of pediatric units, such as otorhinolaryngology or adult units, and pre-hospital deaths could not be captured, potentially leading to underestimation of incidences and disease severity. Variable pathogen-specific underreporting to the NRLs was also observed, which is acknowledged for infectious disease surveillance.³⁷⁻³⁹

In summary, the acute overload of the German pediatric health care system was caused by a post-pandemic rebound of acute viral and bacterial respiratory and invasive diseases that peaked at the same time, creating a fatal combination that caused an unprecedented incidence of hospitalizations in children. Shortages of essential drugs in the outpatient sector ^{40, 41} and a decrease in numbers of operable beds in children's
hospitals due to long-anticipated personnel shortages ^{42, 43} aggravated this pediatric health
care crisis.

520 The results of this study present another piece of evidence that the side effects from 521 preventive measures against the COVID-19 pandemic are at least on par with the harm 522 children experienced from the novel coronavirus itself. While this is already well-523 acknowledged for mental health and obesity, which directly increase morbidity but not 524 mortality 44-47, the wide-spread and drastic increase of severe and fatal bacterial 525 infections in developed countries is new. Worldwide shortages of antibiotics for children ^{40, 41} complicated early treatment in the outpatient setting, which may have caused 526 527 exacerbation of some cases. Despite good overall functional neurological outcomes 528 observed in this study. non-neurological long-term sequelae, especially 529 poststreptococcal autoimmune disorders, may continue to burden the health care system 530 for years.

531 Further research should untangle this amalgam to quantify excess morbidity and mortality that result from acute bacterial infections themselves and from the failure to 532 provide adequate pediatric care capacities in Germany. However, even more urgent than 533 534 scientific workup, is the introduction of effective measures against future outbreaks 535 among children to prevent morbidity and deaths. These include high vaccination 536 coverage, opportunity to acquire natural immunity against viral and bacterial disease, 537 sufficient pediatric drug supply, and pediatric health care capacities adapted to seasonal 538 demands.

539

540 <u>Conclusion</u>

541 The German pediatric health care crisis in late 2022 and early 2023 was caused by

various mechanisms: an increased number of circulating bacterial pathogens, reduced
adaptive immunity in the pediatric population following COVID-19 pandemic isolation
measures, high burden of simultaneous viral infections, shortage of pediatric hospital
capacities, and deficient pediatric antibiotic supply. Considering the upcoming infection
season, an effective action plan including preventive measures needs to be combined
with ongoing infection surveillance to prevent a possible new crisis in pediatric health
care.

549

Acknowledgments

We thank Christina Pentek for her logistic support.

References

- 1. Eden JS, Sikazwe C, Xie R, Deng YM, Sullivan SG, Michie A, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. *Nat Commun*. 2022;13(1):2884.
- 2. Rao S, Armistead I, Messacar K, Alden NB, Schmoll E, Austin E, et al. Shifting Epidemiology and Severity of Respiratory Syncytial Virus in Children During the COVID-19 Pandemic. *JAMA Pediatr.* 2023.
- 3. Farfour E, Clichet V, Péan de Ponfilly G, Carbonnelle E, Vasse M. Impact of COVID-19 pandemic on blood culture practices and bacteremia epidemiology. *Diagn Microbiol Infect Dis.* 2023;107(1):116002.
- 4. Ricketson LJ, Kellner JD. Changes in the Incidence of Invasive Pneumococcal Disease in Calgary, Canada, during the SARS-CoV-2 Pandemic 2020-2022. *Microorganisms*. 2023;11(5).
- 5. Amarsy R, Robert J, Jarlier V. [Impact of the first year of the COVID-19 pandemic on the epidemiology of invasive infections (bacteremia) in the hospitals of the Assistance Publique-Hôpitaux de Paris]. *Bull Acad Natl Med.* 2023;207(2):131-135.
- 6. Cobo-Vázquez E, Aguilera-Alonso D, Carrasco-Colom J, Calvo C, Saavedra-Lozano J. Increasing incidence and severity of invasive Group A streptococcal disease in Spanish children in 2019-2022. *Lancet Reg Health Eur.* 2023;27:100597.
- 7. Guy R, Henderson KL, Coelho J, Hughes H, Mason EL, Gerver SM, et al. Increase in invasive group A streptococcal infection notifications, England, 2022. *Euro Surveill*. 2023;28(1).
- 8. Lassoued Y, Assad Z, Ouldali N, Caseris M, Mariani P, Birgy A, et al. Unexpected Increase in Invasive Group A Streptococcal Infections in Children After Respiratory Viruses Outbreak in France: A 15-Year Time-Series Analysis. *Open Forum Infectious Diseases*. 2023;10(5):ofad188.
- 9. Organization WH. Increased incidence of scarlet fever and invasive Group A Streptococcus infection - multi-country. <u>https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON429</u>. Published 2022. Accessed July 15th, 2022.
- 10. Recent hospital survey reveals: On average, no available intensive care bed for critically ill children Emergency physicians demand new structures. www.divi.de2022.
- 11. <u>https://www.dw.com/en/germany-rsv-infection-wave-overloads-childrens-hospitals/a-63963430</u>. <u>www.dw.com2023</u>.
- 12. "Children are dying because we cannot provide them with care.". <u>www.welt.de</u>: Welt; 2022.
- 13. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *Lancet Digit Health*. 2021;3(6):e360-e370.
- 14. McNeil JC, Flores AR, Kaplan SL, Hulten KG. The Indirect Impact of the SARS-CoV-2 Pandemic on Invasive Group a Streptococcus, Streptococcus Pneumoniae

and Staphylococcus Aureus Infections in Houston Area Children. *Pediatr Infect Dis J*. 2021;40(8):e313-e316.

- 15. Messacar K, Baker RE, Park SW, Nguyen-Tran H, Cataldi JR, Grenfell B. Preparing for uncertainty: endemic pediatric viral illnesses after COVID-19 pandemic disruption. *Lancet*. 2022;400(10364):1663-1665.
- 16. Turner CE. Can group A streptococcus infections be influenced by viruses in the respiratory tract? *Lancet Infect Dis.* 2023;23(2):142-144.
- 17. Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. *Front Microbiol*. 2017;8:1041.
- 18. Thorburn K, Harigopal S, Reddy V, Taylor N, Saene HKFv. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. *Thorax.* 2006;61(7):611.
- 19. Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. *Expert Rev Vaccines*. 2017;16(4):313-328.
- 20. Hellenbrand W, Koch J, Harder T, Bogdan C, Heininger U, Tenenbaum T, et al. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2015;58(11-12):1314-1343.
- 21. Cohen JF, Rybak A, Werner A, Kochert F, Cahn-Sellem F, Gelbert N, et al. Surveillance of noninvasive group A Streptococcus infections in French ambulatory pediatrics before and during the COVID-19 pandemic: a prospective multicenter study from 2018-2022. *Int J Infect Dis.* 2023;134:135-141.
- 22. van Kempen EB, Bruijning-Verhagen PCJ, Borensztajn D, Vermont CL, Quaak MSW, Janson J-A, et al. Increase in Invasive Group a Streptococcal Infections in Children in the Netherlands, A Survey Among 7 Hospitals in 2022. *The Pediatric Infectious Disease Journal*. 2023;42(4).
- 23. de Gier B, Marchal N, de Beer-Schuurman I, te Wierik M, Hooiveld M, Group I-AS, et al. Increase in invasive group A streptococcal (Streptococcus pyogenes) infections (iGAS) in young children in the Netherlands, 2022. *Eurosurveillance*. 2023;28(1):2200941.
- 24. Johannesen TB, Munkstrup C, Edslev SM, Baig S, Nielsen S, Funk T, et al. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023. *Eurosurveillance*. 2023;28(26):2300291.
- 25. Robert-Koch-Institut. Update: Anstieg bakterieller Infektionen durch Gruppe-A-Streptokokken, Pneumokokken und Haemophilus influenzae in Deutschland seit Ende 2022. Berlin: Robert-Koch-Institut; 2023 February 23rd, 2023. Report No.: 8.
- 26. Avire NJ, Whiley H, Ross K. A Review of Streptococcus pyogenes: Public Health Risk Factors, Prevention and Control. *Pathogens*. 2021;10(2).
- 27. Oliver J, Thielemans E, McMinn A, Baker C, Britton PN, Clark JE, et al. Invasive group A Streptococcus disease in Australian children: 2016 to 2018 a descriptive cohort study. *BMC Public Health*. 2019;19(1):1750.
- 28. Buda S, Du□rrwald R, Biere B, Reiche J, Buchholz U, Tolksdorf K, et al. ARE-Wochenbericht KW 25/2023. Arbeitsgemeinschaft Influenza – Robert Koch-Institut. 2023.
- 29. Danino D, Ben-Shimol S, van der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, et al. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of

Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. *Clin Infect Dis.* 2022;75(1):e1154-e1164.

- 30. Chesdachai S, Graden AR, DeSimone DC, Weaver AL, Baddour LM, Joshi AY. Changing Trends of Invasive Pneumococcal Disease in the Era of Conjugate Pneumococcal Vaccination in Olmsted County: A Population-Based Study. *Mayo Clin Proc.* 2022;97(12):2304-2313.
- 31. Deb A, Podmore B, Barnett R, Beier D, Galetzka W, Qizilbash N, et al. Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany. *BMC Infectious Diseases*. 2022;22(1):753.
- 32. Vaccination coverage of children presenting their vaccination card at school entry health examinations. <u>https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_menu_olap?p_uid=gast&p_aid=34430128&p_sprache =E&p_help=0&p_indnr=831&p_indsp=27110398&p_ityp=H&p_fid=. Published 2023. Accessed July 2nd, 2023.</u>
- 33. Laurenz M, von Eiff C, Borchert K, Jacob C, Seidel K, Schley K. Vaccination rates and adherence in pneumococcal conjugate vaccination in mature born infants before and after vaccination schedule change A claims database analysis. *Vaccine*. 2021;39(24):3287-3295.
- 34. Nuttens C, Findlow J, Balmer P, Swerdlow DL, Tin Tin Htar M. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. *Euro Surveill*. 2022;27(3).
- 35. Robert-Koch-Institut. Invasive Meningokokken-Erkrankungen 2012 2015. Berlin: Robert-Koch-Institut; 2016 October 31st, 2016.
- 36. Steens A, Knol MJ, Freudenburg-de Graaf W, de Melker HE, van der Ende A, van Sorge NM. Pathogen- and Type-Specific Changes in Invasive Bacterial Disease Epidemiology during the First Year of the COVID-19 Pandemic in The Netherlands. *Microorganisms*. 2022;10(5).
- 37. Doyle TJ, Glynn MK, Groseclose SL. Completeness of Notifiable Infectious Disease Reporting in the United States: An Analytical Literature Review. *American Journal of Epidemiology*. 2002;155(9):866-874.
- 38. Meadows AJ, Oppenheim B, Guerrero J, Ash B, Badker R, Lam CK, et al. Infectious Disease Underreporting Is Predicted by Country-Level Preparedness, Politics, and Pathogen Severity. *Health Secur.* 2022;20(4):331-338.
- 39. Gibbons CL, Mangen M-JJ, Plass D, Havelaar AH, Brooke RJ, Kramarz P, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. *BMC Public Health*. 2014;14(1):147.
- 40. Shachar C, Gruppuso PA, Adashi EY. Pediatric Drug and Other Shortages in the Age of Supply Chain Disruption. *Jama*. 2023;329(24):2127-2128.
- 41. Reali L, Mendie C, Fischbach T, Werner A, Leitner AY, Karall D, et al. Open letter: The health of our children and adolescents is endangered throughout Europe due to the medication shortage. <u>www.bvkj.de2023</u>.
- 42. Parvu V. Alarming study results: Physicians warn of supply crisis in German children's hospitals. <u>www.divi.de2019</u>.
- 43. DIVI criticizes staff shortage in pediatric intensive care units in Germany. <u>www.divi.de2018</u>.
- 44. Chang TH, Chen YC, Chen WY, Chen CY, Hsu WY, Chou Y, et al. Weight Gain Associated with COVID-19 Lockdown in Children and Adolescents: A Systematic Review and Meta-Analysis. *Nutrients*. 2021;13(10).
- 45. Viner R, Russell S, Saulle R, Croker H, Stansfield C, Packer J, et al. School Closures During Social Lockdown and Mental Health, Health Behaviors, and Well-

being Among Children and Adolescents During the First COVID-19 Wave: A Systematic Review. *JAMA Pediatr*. 2022;176(4):400-409.

- 46. Bruns N, Willemsen L, Stang A, Kowall B, Holtkamp K, Kamp O, et al. Pediatric Intensive Care Unit Admissions After Adolescent Suicide Attempts During the Pandemic. *Pediatrics*. 2022.
- 47. Meherali S, Punjani N, Louie-Poon S, Abdul Rahim K, Das JK, Salam RA, et al. Mental Health of Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic Review. *Int J Environ Res Public Health*. 2021;18(7).

Tables

Table 1: International classification of diseases codes used to calculate the number of expected deaths from bacterial infections in children in Germany

Pathogen	ICD-10-GM code		
Streptococci (all species)	A40.0-A40.3, A40.8, A40.9, A46, A49.1, G00.1, G00.2,		
	J03.0, J13, J15.3, J15.4, J20.2, M00.2, J02.0		
N. meningitidis	A39.0-A39.4, A39.8, A39.9		
H. influenzae	A41.3, A49.2, J14		

ICD-10-GM = international classification of diseases 10 (German modification)

1	Total	S. pyogenes	S. pneumoniae	H. influenzae	N. meningitidis	S. spp.*
	N = 153	n = 58	n = 62	n = 19	n = 2	n = 12
	(100%)	(38 %)	(41 %)	(12 %)	(1 %)	(8 %)
Male, <i>n</i> (%)	86 (56%)	39 (67 %)	30 (48 %)	10 (53 %)	1 (50 %)	6 (50 %)
Age in years, median (IQR)	4 (1 – 7)	4 (2 – 7)	2.5(1-5)	3 (0 – 6)	9.5 (2 - 17)	3.5(0.5-8.5)
Viral co-infection, <i>n</i> (%)	71 (46 %)	18 (31 %)	37 (60 %)	14 (74 %)	0 (0 %)	2 (17 %)
RSV, <i>n</i> (%)	21 (14 %)	2 (3 %)	10 (16 %)	8 (41 %)	0(0%)	1 (8 %)
Influenza A/B, <i>n</i> (%)	29 (19 %)	12 (21 %)	14 (23 %)	3 (16 %)	0(0%)	0 (0 %)
SARS-CoV-2, <i>n</i> (%)	3 (2 %)	1 (2 %)	2 (3 %)	0(0%)	0(0%)	0(0%)
Other, n (%)	24 (16 %)	4 (7 %)	17 (27 %)	3 (16 %)	0 (0 %)	1 (8 %)
Bacterial co-infection with <i>H. influenzae</i> , n (%)	12 (8 %)	1 (2 %)	10 (16 %)	-	0(0%)	1 (8 %)
Clinical presentation						
Sepsis, SIRS, Toxic Shock, n (%)	28 (18 %)	18 (31 %)	1 (2 %)	1 (5 %)	1 (50 %)	7 (58 %)
ENT infections w/o cerebral invasion, n (%)	22 (14 %)	16 (28 %)	3 (5 %)	2 (11 %)	0 (0 %)	3 (25 %)
ENT infections w/ cerebral invasion, n (%)	15 (5 %)	9 (2 %)	6 (10 %)	0 (0 %)	0 (0 %)	0(0%)
CNS infection, n (%)	15 (10 %)	5 (9 %)	4 (7 %)	0(0%)	2 (100 %)	4 (33 %)
Pneumonia, n (%)	91 (59 %)	22 (38 %)	51 (82 %)	15 (79 %)	0 (0 %)	3 (25 %)
Skin and soft tissue infections, n (%)	22 (14 %)	17 (29 %)	4 (7 %)	0(0%)	0(0%)	1 (8 %)
Other infections, n (%)	5 (3 %)	2 (3 %)	0 (0 %)	1 (5 %)	0(0%)	3 (25 %)
Treatment						
Resuscitation, n (%)	6 (4 %)	5 (9 %)	0 (0 %)	1 (5 %)	0(0%)	0(0%)
PICU admission, n (%)	90 (59 %)	29 (50 %)	42 (68 %)	12 (63 %)	2 (100 %)	4 (33 %)
Invasive ventilation, n (%)	67 (44 %)	23 (40 %)	28 (45 %)	12 (63 %)	1 (50 %)	3 (25 %)
Administration of vasopressors/inotropes, n (%)	26 (17 %)	14 (24 %)	7 (11 %)	5 (26 %)	0(0%)	0(0%)
Extracorporeal membrane oxygenation, n (%)	1(1%)	1 (2 %)	0 (0 %)	0(0%)	0(0%)	0(0%)
Surgical source control, n (%)	41 (27 %)	22 (38 %)	14 (23 %)	0(0%)	0 (0 %)	7 (58 %)
Length of hospital stay hospital, median (IQR)	10 (5 – 19)	8 (4 – 19)	11 (5 – 19)	5 (4 - 6)	6 (1 - 11)	13 (7.5 – 25.5)
Discharge to rehabilitation/care facility, n (%)	5 (3 %)	2 (3 %)	2 (3 %)	0 (0%)	0 (0%)	1 (8 %)
PCPC at hospital discharge, median (IQR)	1(1-2)	1 (1 – 2)	1 (1 – 2)	1(1-2)	1 (1 – 1)	1 (1 – 2)
Deceased, n (%)	8 (5 %)	5 (9 %)	2 (3 %)	1 (5 %)	0 (0 %)	0 (0 %)

Table 2: Clinical characteristics of hospital admissions due to bacterial infections reported in a multicentre study in children's hospitals in North Rhine-Westphalia (Germany) between October 1st and December 31st, 2022

-

*Streptococcal species other than *S. pyogenes* and *S. pneumoniae*, IQR = interquartile range; ENT = ears nose and throat; CNS = central nervous system; SIRS = systemic inflammatory response syndrome, PICU = pediatric intensive care unit; PCPC = Pediatric Cerebral Performance Category

Table 3: National surveillance and multicentre study detection of pediatric severe and
invasive bacterial infections between October 1 st and December 31 st of 2022 in North-
Rhine Westphalia (Germany)

Pathogen	Detection by		Estimated number of non-captured cases	Estimated total number of cases	
	NRL	MC	NRC + MC		
	Ν	n	n	n (95 % CI)	n
S. pyogenes	18	58	5	138 (48 - 400)	214
S. pneumoniae	18	63	5	151 (52 – 437)	232
N. meningitidis	6	2	2	$0 (0 - 0)^*$	6
H. influenzae	6	31**	2	58 (10 - 329)	95

NRL = National reference laboratory, MC = multicentre study, *exact estimate: 2.1E-11 (9.4E-12 - 4.6E-11), **primary and co-infections included

Pathogen	Expected number of deaths in Germany per year*	Expected number of deaths in NRW per year*	Observed number of deaths in multicentre study in last quarter of 2022
Streptococci (all species)	4	0.9	7
N. meningitidis	8	1.8	0
H. influenzae	0.3	0.1	0

Table 4: Expected and observed number of deaths in children < 15 years in Germany categorized by pathogen

*based on national death cause statistics 2016 - 2019

Figure legends

Figure 1. Hospital-treated community-acquired bacterial infections in children in North Rhine-Westphalia in the last quarter of 2022

a) Clinical presentation

b) Treatment and outcomes

SIRS = systemic inflammatory response syndrome; TSS = toxic shock syndrome, ENT = ear-nose-throat; CNS = central nervous system; ICU = intensive care unit; CPR = cardiopulmonary resuscitation

Figure 2. Hospitalizations for community-acquired bacterial infections

- a) S. pyogenes
- b) S. pneumoniae
- c) N. meningitidis
- d) H. influenzae

Red solid line: incidence rates January 2020 - March 2023; black dashed line and grey band: average monthly incidence rates 2016 - 2019 with 95 % CI; green band: period of MC study

Figure 3. Hospitalizations due to acquired-bacterial infections from S. pyogenes, S. pneumoniae, N. meningitidis, and H. influenzae, January 2020 - March 2023 a) Cumulative hospitalization rates of S. pneumoniae (dark grey), S. pyogenes

(medium grey), and N. meningitidis + H. influenzae (light grey)

b) IRRs of infections, reference period 2016 – 2019

Green band: period of MC study

Figure S1. Monthly incidence rate ratios of invasive bacterial infections in children in North Rhine-Westphalia January 2020 - March 2023 (reference period 2016 – 2019)

- a) S. pyogenes
- b) S. pneumoniae
- c) N. meningitidis
- d) H. influenzae



a)



01/2021

07/2021

07/2020

07/2022

01/2022

01/2023

0

01/2020







